CRISPR Therapeutics
CRSP
CRSP
396 hedge funds and large institutions have $2.45B invested in CRISPR Therapeutics in 2022 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 117 increasing their positions, 120 reducing their positions, and 87 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
34% less capital invested
Capital invested by funds: $3.7B → $2.45B (-$1.25B)
36% less first-time investments, than exits
New positions opened: 56 | Existing positions closed: 87
63% less funds holding in top 10
Funds holding in top 10: 8 → 3 (-5)
Holders
396
Holding in Top 10
3
Calls
$109M
Puts
$86.2M
Top Buyers
| 1 | +$30.6M | |
| 2 | +$20.8M | |
| 3 | +$11.5M | |
| 4 |
Barclays
London,
United Kingdom
|
+$11.4M |
| 5 |
PI
PEAK6 Investments
Chicago,
Illinois
|
+$11.1M |
Top Sellers
| 1 | -$87.8M | |
| 2 | -$42.4M | |
| 3 | -$32.4M | |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$16.6M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
-$14.4M |